Recently, the "Fourteen Provinces (Autonomous Regions, Corps) Centralized Drug Procurement Document (Draft for Comments)" released by the Shaanxi Provincial Centralized Procurement Platform for Drugs and Devices shows that 14 provinces, municipalities and autonomous regions such as Heilongjiang and Guangxi led by Shaanxi voluntarily formed an inter-provincial alliance to carry out inter-provincial centralized drug procurement. According to the requirements of centralized procurement, the procurement cycle of this alliance is two years in principle, and the procurement agreement is signed once a year during the procurement cycle.
Screenshot source: Shaanxi Provincial Centralized Procurement Platform for Pharmaceutical Equipment
The centralized procurement is divided into two groups, A and B, according to the relevant qualifications of the bidding varieties, and competes separately. The two groups A and B will conduct quotation and comprehensive evaluation respectively. Group A includes reference preparations, over-evaluated/deemed generic drugs, and Group B is other drugs; If the varieties that meet the conditions of Group A are voluntarily declared to be included in Group B, the economic and technical standards of the enterprise will be fully scored. The rules for the proposed selection are divided according to exclusive or non-exclusive declaration:
(1) Those who declare exclusively and the quotation reduction rate meets the standard, or there is a centralized procurement in other provinces, will be directly selected;
(2) Non-exclusive declarations will be ranked according to the comprehensive evaluation score (economic and technical standard ×50% + commercial standard ×50%), and the winner will be determined within the quota.
In addition, the resurrection mechanism is set up in this centralized procurement, and the unselected varieties have the opportunity to be resurrected, but the purchase volume of the resurrection enterprises is halved and does not participate in the amount to be distributed. There are 19 kinds of drugs involved in this centralized procurement, with injections dominating, and therapeutic drugs covering blood and hematopoietic system drugs, nervous system drugs, digestive system and metabolic drugs.
It is proposed to be included in the list of 14 provincial alliances for centralized procurement of drugs
Among them, there are heparin sodium injection, glutathione, polysaccharide iron complex and other varieties, and the sales of the national hospital market will exceed 800 million yuan in 2023. It is understood that heparin sodium, as a high-end product in the heparin value chain, has a huge market size, and the sales of heparin sodium injection in the national hospital market will exceed 1.1 billion yuan in 2023, ranking among the top 20 blood and hematopoietic system drugs.
Screenshot source: Yaorongyun National Hospital Sales Database
According to the pharmaceutical finance cloud database, in the competition in the hospital market of heparin sodium injection, Chengdu Haitong Pharmaceutical leads with a share of 32.81%, Changzhou Qianhong Biochemical Pharmaceutical follows with 25.20%, and Jiangsu Wanbang Biochemical Pharmaceutical Group ranks third with 14.38%. At present, there are 23 pharmaceutical companies in the domestic market that have production approvals.
Screenshot source: Yaorongyun National Hospital Sales Database
In addition, the sales of glutathione for injection in the national hospital market in 2023 will be nearly 1 billion yuan, of which Shandong Luye Pharmaceutical leads with a market share of 27.25%, Shanghai Fudan Fuhua Pharmaceutical ranks second with a market share of 26.35%, and Shandong Luoxin Pharmaceutical ranks third with a market share of 5.83%.
Screenshot source: Yaorongyun China Drug Approval Database
Overall, although the number of drugs involved in this centralized procurement is not large, and the rules are not difficult, there is still a certain price reduction pressure for enterprises because the procurement varieties and alliance members overlap with the centralized procurement projects in the past two years, and the comprehensive review rules are applicable in the case of non-exclusive declaration.
Yaorong Cloud's brand upgrade activities are wonderful, and there are many things you don't know~
On October 23, 2024, the brand image and name of Yaorongyun will be fully upgraded to "Moentropy Digital", in order to witness this historic transformation, and to extend our deepest respect and gratitude to our customers who have supported us for a long time, we will send the most sincere gratitude feedback and generous benefits to new and old users: iPhone 16 is free to give, registration is free VIP experience, new friends can enjoy up to 50,000 yuan limited-time special offer, free 20+ professional report gift package, new product special area unlock 5% off surprise...... Stay tuned and look forward to it!
<END>